Carbamazepine (Tegretol)
What studies of Carbamazepine (Tegretol) found
At a glance, by condition
Long COVID: C Might help, very uncertain
Based on the strongest evidence, studies with no comparison group (very low certainty), for smell and taste loss.
1 outcome rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Carbamazepine (Tegretol) might help some people with long COVID, but research can’t show it yet. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Carbamazepine (Tegretol) · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Smell and taste loss1 study · 10 people took Carbamazepine (Tegretol) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people (10 in all); not all results were tested against chance.
Studies with no comparison group10 in the study · 11 weeks, except one patient stopped after 1 month · An initial dosage of 100 mg/day of carbamazepine was administered for three consecutive days; the dose was then increased by 100 mg/day every 5 days until it reached 400 mg/day, 100 mg/day for three consecutive days; then increased by 100 mg/day every 5 days until 400 mg/day
Smell and taste loss improved.
The evidence is very uncertain about the effect of carbamazepine (Tegretol) on smell and taste loss in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people (10 in all)
- Not all results were tested against chance
See the 1 study
-
Post-COVID-19 olfactory dysfunction: carbamazepine as a treatment option in a series of cases. (2022)
- People in the study
- 10 in the study
- Dose
- An initial dosage of 100 mg/day of carbamazepine was administered for three consecutive days; the dose was then increased by 100 mg/day every 5 days until it reached 400 mg/day, 100 mg/day for three consecutive days; then increased by 100 mg/day every 5 days until 400 mg/day
- Outcome
- improved olfactory function
- Effect
- better (not tested)
- Risk of bias
- case report or series (JBI checklist for case reports / case series); not rated with RoB 2 or ROBINS-I
Side effects
Side effects studies reported1 kind
| Side effect | Studies that reported it |
|---|---|
| Dizziness | 1 study |
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
100 to 600 mg at the start
- 2Raise
Raised step by step in 1 of 2 studies
- 3Top dose
Most often 400 mg (1 of 2 studies)
Doses across 2 studies
100 to 600 mg.
Each study’s dose, as printed
- An initial dosage of 100 mg/day of carbamazepine was administered for three consecutive days; the dose was then increased by 100 mg/day every 5 days until it reached 400 mg/day, 100 mg/day for three consecutive days; then increased by 100 mg/day every 5 days until 400 mg/day Post-COVID-19 olfactory dysfunction: carbamazepine as a treatment option in a series of cases. (2022)
- 600 mg, daily Case report: post COVID-19 encephalopathy and oral cenesthopathy. (2025)
All papers
- Case report: post COVID-19 encephalopathy and oral cenesthopathy.2025 · case report · 1 in the study
Summary
This case report described one 73-year-old female who developed post COVID-19 encephalopathy, followed by major depression and oral cenesthopathy 16 months after infection. She first presented to the authors' Psychiatric Outpatient Department and was later admitted to their psychiatric ward. She received Aripiprazole 5 mg and Carbamazepine 600 mg daily; duration was not reported. There was no comparison group. Outcomes reported within the same patient were partial symptom improvement; the intensity of her oral discomfort diminished and she appeared less agitated and depressed; Carbamazepine showed minimal efficacy and the response was minimal; she was discharged with partial improvement under the same regimen. An attempt to titrate Aripiprazole to 7.5 mg led to unsteady gait and a fall, necessitating reduction back to 5 mg. The abstract also states symptom control was limited by medication side effects, and the discussion states dose escalation was limited by side effects. The authors state treatment of oral cenesthopathy remains challenging and further research is needed.
- Post-COVID-19 olfactory dysfunction: carbamazepine as a treatment option in a series of cases.2022 · case report · 10 in the study
Summary
This case series included 10 patients (9 women and 1 man) with persistent post-COVID-19 olfactory dysfunction (anosmia/parosmia). Carbamazepine was started at 100 mg/day for three consecutive days and increased by 100 mg/day every 5 days until 400 mg/day; it was administered for 11 weeks. One patient stopped using the medication after 1 month of treatment; drowsiness and dizziness were reported. The median duration of drug treatment was 51.5 days (range: 36–118 days). There was no comparison group. Treatment efficacy was evaluated by questioning each patient about changes or improvement in olfactory ability. Nine of the 10 patients reported improved olfactory function after carbamazepine treatment; 5 patients (50%) reported complete improvement, 1 reported extensive but not complete improvement, 3 considered improvement mild, and 1 reported no improvement. Improvement was reported from 1 patient at 400 mg/day, 5 patients at 300 mg/day, 1 patient at 200 mg/day, and 2 patients at 100 mg/day. Adverse effects reported were drowsiness (9/10) and dizziness (2/10). The authors state the role of carbamazepine in controlling post-COVID-19 olfactory dysfunction could not be confirmed; they note the lack of a comparison group and that only 6 patients were able to receive MRI.
- Severe ME in Children.2020 · combination: given with other treatments
Summary
The paper presents a series of case reports of individual cases to illustrate clinical presentation and general principles of management of severe paediatric ME/CFS. The author writes that there is very limited data on patients who are very severe, housebound or bedbound. No number of patients, clinic setting, comparison group or formal outcome measures are reported. Treatments described across the cases include nasogastric or nasojejunal tube feeding, intramuscular immunoglobulin monthly for 12 months, amitriptyline, carbamazepine, clarithromycin, doxycycline, opiates, a urinary catheter, active physiotherapy for three months and Tender Loving Care. The paper reports that one case made a very slow recovery, with tube feeding stopped after 3 years, and was operating at 95% of normal 20 years later; another made a full recovery by the end of two years; another recovered completely within 12 months after clarithromycin was changed to doxycycline and had no relapses at follow up 12 years later; and Case A made a full spontaneous recovery. Case B received active physiotherapy for three months, deteriorated further and remained severely affected 20 years later. Case C died. Harms include a traumatic hospital experience, a convulsive myoclonic jerk from noise and sensory overload. The author states that one should not draw too many conclusions from one case.
- Pharmacologic and Nonpharmacologic Treatment of Long COVID: A Meta-narrative Review2025 · review
Summary
This meta-narrative review evaluated pharmacologic and nonpharmacologic treatments for long COVID, defined as persistent symptoms 4 weeks or longer after acute COVID-19. The authors searched English-language articles from November 2019 through December 2023 and included 51 studies. Most included studies reported nonpharmacologic treatments, with fatigue the most prevalent symptom. Interventions described included therapeutic exercise, nutritional supplements, oxygen-ozone autohemotherapy, rehabilitation, molecular hydrogen therapy, hyperbaric oxygen, epipharyngeal abrasive therapy, Qingjin Yiqi granules, pomegranate juice with sumac, remdesivir, antibody-based therapies, and intranasal corticosteroids. Findings varied by study: some reported improvements in fatigue, dyspnea, cognitive symptoms, chest pain, immunodeficiency, or olfactory dysfunction. The review also reported no significant reduction in number or severity of long COVID–related symptoms with high-dose CoQ-10 compared with placebo; no significant difference in symptoms and mortality risks between nirmatrelvir/ritonavir and no treatment groups; smell score differences not statistically significant with corticosteroid nasal irrigation; and no effect of olfactory training on olfactory test scores. In Pehlivan et al., 6 cases were dropped for several reasons. The authors state the evidence is limited and of low quality.